



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,946	08/18/2003	James W. Ryan	JR-14000-CON	4300

7590

10/17/2006

Cheryl H. Agris, Ph.D.  
P.O. Box 806  
Pelham, NY 10803

EXAMINER
----------

ZARA, JANE J

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 10/17/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/642,946

Applicant(s)

RYAN, JAMES W.

Examiner

Jane Zara

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 07 September 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-4,6-16 and 23-26 is/are pending in the application.
- 4a) Of the above claim(s) 7,9,12,13 and 23-26 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4,6,8,10,11 and 14-16 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 1-29-04.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☒ Other: \_\_\_\_\_.

Art Unit: 1635

### **DETAILED ACTION**

This Office action is in response to the communication filed 9-7-06.

Claims 1-4, 6-16, 23-26 are pending in the instant application.

#### ***Election/Restrictions***

Applicant's election with traverse of Group I, claims 1-4, 6, 8, 10, 11 and 14-16, and SEQ ID No. 6 in the reply filed on 9-7-06 is acknowledged. The traversal is on the ground(s) that Groups II-IV are ultimately linked to the claims in Group I and are subject to the right of rejoinder one there is indication of allowable subject matter of Group I. Applicant also argues that no undue burden would exist to search all of the sequences originally claimed in addition to the elected sequence. This is not found fully persuasive because the searches required for proper examination of all of the sequences and all of the different methods claimed would be burdensome to the examiner and, even though the searches of the prior art and appropriate data bases for some of the sequences and groups might be overlapping, they would not be coextensive. Applicant is correct that the linking claims would be rejoined upon allowance of the elected Group, provided that the methods were commensurate in scope with the allowed composition claims.

The requirement is still deemed proper and is therefore made FINAL.

Claims 7, 9, 12, 13, 23-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there

Art Unit: 1635

being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 9-7-06.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4, 6, 8, 10, 11 and 14-16 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to compositions comprising isolated genomic nucleic acid molecules having a nucleotide sequence at least 95% identical to any polynucleotide encoding the polypeptide of SEQ ID NO. 3, or any nucleic acid molecule that hybridizes to these polynucleotides, and isolated nucleic acids comprising at least 20 nucleotides that hybridize with high stringency to an intronic region of SEQ ID No. 6.

The specification, claims and the art do not adequately describe the distinguishing features or attributes concisely shared by the members of the genus comprising these nucleic acids that are at least 95% homologous to any polynucleotide that encodes the polypeptide of SEQ ID NO. 3, or nucleic acids

Art Unit: 1635

that specifically hybridize to them, or any polynucleotide that stringently hybridizes to the intronic sequences of SEQ ID No. 6. The specification teaches the sequence of SEQ ID No. 6, encoding the polypeptide of SEQ ID NO. 3. The genus of nucleic acids claimed, however, encompasses a myriad of structures (e.g. thousands and thousands of nucleic acid sequences) and the specification and claims do not adequately teach a representative number of species for the broad genus claimed, and which provide for the function claimed, of having human adipocyte enhancer binding protein 1 activity.

Concise structural features that could distinguish structures within the genus from others are missing from the disclosure. No common structural attributes identify the members of the claimed genus, and distinguish members within the claimed genus from those outside of it, and which provide for the function claimed, of having human adipocyte enhancer binding protein 1 activity. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus claimed.

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this

Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1635

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4, 6 and 10 are rejected under 35 U.S.C. 102(b) as being anticipated by Layne et al.

Layne et al (J. Biol. Chem., Vol. 273, No. 25, pages 15,654-15,660, 1998) teach compositions and methods of recombinant polypeptide expression in vitro comprising the nucleic acid encoding the polypeptide of SEQ ID NO. 3 and further comprising a carrier (e.g. water), as well as an expression vector and recombinant host cells comprising the nucleic acid encoding the polypeptide of SEQ ID No. 3 (see the abstract on p. 15,654, text on p. 15,655, fig. 1 on p. 15,656, discussion on pp. 15,658-9. See also the accompanying alignment between SEQ ID No. 3 of the instant application and AF053944 of Layne et al).

Claims 8 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Noonberg et al.

Noonberg et al (USPN 5,624,803) teach a compositions comprising a polynucleotide at least 20 nucleobases in length that specifically hybridizes under stringent condition with an intronic sequence of SEQ ID NO. 6 and further comprising a carrier, water (see the accompanying sequence alignment data between nucleotides 3002-3237 of SEQ ID NO. 6 and SEQ ID No. 20 of

Art Unit: 1635

Noonberg et al. In the alignment data, nucleotide no. 3002 of SEQ ID No. 6 = nucleotide no. 1).

Claims 8 and 11 are rejected under 35 U.S.C. 102(e) as being anticipated by Denney et al.

Denney et al (USPN 5,972,334) teach a compositions comprising a polynucleotide at least 20 nucleobases in length that specifically hybridizes under stringent condition with an intronic sequence of SEQ ID NO. 6 and further comprising a carrier, water (see the accompanying sequence alignment data between nucleotides 1967-2208 of SEQ ID NO. 6 and SEQ ID No. 35 of Denney et al. In the alignment data, Nucleotide no. 3002 of SEQ ID No. 6 = nucleotide no. 1).

### ***Conclusion***

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is **571-273-8300**. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571)**

Art Unit: 1635

**272-0765.** If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras, can be reached on (571) 272-4517. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**Jane Zara**  
10-10-06

  
TC1600  
JANE ZARA, PH.D.  
PRIMARY EXAMINER







Qy 781 GlnGluGlnLeuLeuAlaAlaAlaMetAlaAlaArgGlyGluAspGluAspGluVal 800  
Db 2480 CAGGACAGCTGCTGCCGAGCATGGCGAGAGCCCGGGGGAGGATGGAGGAGGTC 2539  
Qy 801 SerGluAlaGlnGluThrProAspHisAlaIlePheArgTrpLeuAlaIleSerPheAla 820  
Db 2540 TCGAGGCCGAGGAGACTCCAGACCGCATCTCCGGTGGCTGTCATCTCTCTCGCC 2599  
Qy 821 SerAlaHisLeuThrLeuThrGluProTyrArgGlyGlyCysGlnAlaGlnAspTyrThr 840  
Db 2600 TCGGCACACTCACTTACCGAGCCCTACCGGGAGGCTGCCAAGCCGAGGACTACAC 2659  
Qy 841 GlyGlyMetGlyIleValAlaGlyValAlaTyrAsnProArgThrGlyThrIleAsnAsp 860  
Db 2660 GCGCGCATGGCATCGTCAACGGGGCCAGTGGAAACCCCGGAGCGGACTATCATGAC 2719  
Qy 861 PheSerTyrLeuHisThrAsnCysLeuGluLeuSerPheTyrLeuGlyCysAspLysPhe 880  
Db 2720 TTCACTTACCTGCATACCAACTGCTGGAGCTCTCTCTTCTACCTGGGCTGTGACAAAGTTC 2779  
Qy 881 ProHisGluSerGluLeuProArgGluTyrGluAsnAsnLysGluAlaLeuThrPhe 900  
Db 2780 CCTCATGAGTGTAGTGGCCCGGAGTGGGAGAACAAACAGGAGGCGCTGCACCTTC 2839  
Qy 901 MetGluGlnValHisArgGlyIleLysGlyValValThrAspGluGlnGlyIleProIle 920  
Db 2840 ATGAGCAGGTGCACCGCGCATTAAGGGGTGGTGGAGCGAGCGAGCATCCCATTC 2899  
Qy 921 AlaAsnAlaThrIleSerValSerGlyIleAsnHisGlyValLysThrAlaSerGlyGly 940  
Db 2900 GCCAACGCCACCATCTCTGTGAGTGGCATTAATCAGCGGTGAAGACAGCAGTGGTGGT 2959  
Qy 941 AspTyrTrpArgIleLeuAsnProGlyGluTyrArgValThrAlaHisAlaGluGlyTyr 960  
Db 2960 GATTACTGGCGAATCTTGAACCGGGGTGAGTCCGGGTGACGCCACCGGGAGGCTAC 3019  
Qy 961 ThrProSerAlaLysThrCysAsnValAspTyrAspIleGlyAlaThrGlnCysAsnPhe 980  
Db 3020 ACCCGAGCGCCAGACCTGCATGTGACTATGACATCGGGGCCATCTAGTGCACACTTC 3079  
Qy 981 IleLeuAlaArgSerAsnTrpLysArgIleArgGluIleMetAlaMetAsnGlyAsnArg 1000  
Db 3080 ATCTGTGCTCGCTCCAACTGAGAGCGCATCCGGAGATCATGCGCATGAACGGACCGG 3139  
Qy 1001 ProIleProHisIleAspProSerArgProMetThrProGlnGlnArgLeuGlnGln 1020  
Db 3140 CCTATCCACACATAGACCCATCGGCCCTATGACCCCCCAACAGCGACGCCCTGCACG 3199  
Qy 1021 ArgArgLeuGlnHisArgLeuArgLeuArgAlaGlnMetArgLeuArgArgLeuAsnAla 1040  
Db 3200 CGACGCTTACACACCCGCTCGGGCTTCGGGCGACAGATGCGGTGCGGCGGCTCAACGCC 3259  
Qy 1041 ThrThrThrLeuGlyProHisThrValProProThrLeuProProAlaProAlaThrThr 1060  
Db 3260 ACCACACCCCTAGSCCCCAACATGTGCTCCCTCCAGGCTGCCCTGCGCCCTGCACACC 3319  
Qy 1061 LeuSerThrThrIleGluProTrpGlyLeuIleProProThrThrAlaGlyTrpGluGlu 1080  
Db 3320 CTGAGCACTACCATAGAGCCCTGGGGCTTCATACCCGCAACCCACCGCTGCTGGAGGAG 3379  
Qy 1081 SerGluThrGluThrTyrThrGluValValThrGluPheGlyThrGluValGluProGlu 1100  
Db 3380 TCGAGACTGAGACCTTACACAGAGTGTGTACAGAGTTTGGACCGAGGTGGAGCCCGG 3439  
Qy 1101 PheGlyThrLysValGluProGluPheGluThrGlnLeuGluProGluPheGluThrGln 1120  
Db 3440 TTTGGGACCAAGGTGGAGCCCGAGTTTGAGACCCAGTTGGAGCTGAGTTCGAGACCCAG 3499  
Qy 1121 LeuGluProGluPheGluGluGluGluGluGluGluGluGluGluGluGluGluGly 1140  
Db 3500 CTGGAACCCGAGTTTGGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 3559  
Qy 1141 GlnAlaPheProPheThrThrValGluThrThrValAlaAsnPheGlyAspPhe 1158

Db 3560 CAGGCATTCCTCTCACACAGTAGACACTACAGTGAACCTTGGGACTTC 3613  
RESULT 4  
BC038588  
LOCUS  
DEFINITION  
IMAGE:5764769, complete cds.  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
PUBMED  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
REMARK  
COMMENT  
Contact: MGC help desk  
Email: cgabbs@mail.nih.gov  
Tissue Procurement: Life Technologies, Inc.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: National Institutes of Health Intramural Sequencing Center (NISC), Gaithersburg, Maryland;  
Web site: http://www.nisc.nih.gov/  
Contact: nisc.mgc@nih.gov  
Akhter, N., Ayala, K., Beckstrom-Sternberg, S.M., Benjamin, B., Blakesley, R.W., Bouffard, G.G., Breen, K., Brinkley, C., Brooks, S., Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P., Hansen, N., Ho, S.-L., Karlins, E., Kwong, P., Laric, P., Legaspi, R., Maduro, Q.L., Masiello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C., McDowell, J., Pearson, R., Stantripop, S., Thomas, P.J., Touchman, J.W., Tsurgeon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L., Young, A., Zhang, L.-H. and Green, E.D.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov  
Series: IRAC Plate: 79 Row: P Column: 19  
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 4755145.  
Location/Qualifiers  
1. .4125

STATE: CA  
COUNTRY: USA  
ZIP: 94304-1018  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/324,001  
FILING DATE: 13-OCT-1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: MONROY, GLADYS H.  
REGISTRATION NUMBER: 32,430  
REFERENCE/DOCKET NUMBER: 22000-20544.20  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 813-5600  
TELEFAX: (415) 494-0792  
TELEX: 706141 MRSN FOERSSFO  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 43 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
US-08-324-001-19

Query Match	8.8%;	Score 20.9;	DB 2;	Length 43;
Best Local Similarity	78.1%;	Pred. No. 3.2e+03;		
Matches	25;	Conservative	0; Mismatches	7; Indels
			0; Gaps	0;
QY	137	CACGTGTCGCCCTTCTCCTTCTGCCATGATT	168	
Db	10	CTCTCTCTCCACCTCTCTCTCTCTCTGATT	41	

102b

RESULT 3  
US-08-324-001-20/c  
Sequence 20, Application US/08324001  
Patent No. 5624803  
GENERAL INFORMATION:  
APPLICANT: NOONBERG, SARAH B.  
APPLICANT: HUNT, C. ANTHONY  
TITLE OF INVENTION: IN VIVO OLIGONUCLEOTIDE GENERATOR, AND  
TITLE OF INVENTION: METHODS OF TESTING THE BINDING AFFINITY OF TRIPLEX FORMING  
TITLE OF INVENTION: OLIGONUCLEOTIDES DERIVED THEREFROM  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MORRISON & FOERSTER  
STREET: 755 PAGE MILL ROAD  
CITY: PALO ALTO  
STATE: CA  
COUNTRY: USA  
ZIP: 94304-1018  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/324,001  
FILING DATE: 13-OCT-1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: MONROY, GLADYS H.  
REGISTRATION NUMBER: 32,430  
REFERENCE/DOCKET NUMBER: 22000-20544.20  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 813-5600  
TELEFAX: (415) 494-0792  
TELEX: 706141 MRSN FOERSSFO  
INFORMATION FOR SEQ ID NO: 20:

```

;
;
; LENGTH: 43 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-324-001-20

```

Query Match 8.8%; Score 20.8; DB 2; Length 43;  
Best Local Similarity 78.1%; Pred. No. 3.2e+03;  
Matches 25; Conservative 0; Mismatches 7; Indels

QY-2.2.1. 137 CACCTGCTCCCCCTTCTCTCTGCCATGATT 168

Db 34 CTCTCTCTCCACCTCTCTCTCTCTCTGTGATT 3

```

RESULT 4
US-10-131-827-584
; Sequence 584, Application US/10131827
; Patent No. 6905827
; GENERAL INFORMATION:
; APPLICANT: Wohlgenuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Lv, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,612
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,612
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 584
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-584

```

[illegible]

```

RESULT 5
US-10-131-831-584
; Sequence 584, Application US/10131831
; Patent No. 7026121
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING
; FILE OF INVENTION: TRANSPLANT REJECTION
; FILE REFERENCE: 506612000121
; CURRENT APPLICATION NUMBER: US/10/131,831
; CURRENT FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9190
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 584
; LENGTH: 50

```

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

**TITLE OF INVENTION:** SUBUNIT N-METHYL

RESULT 9  
US-08-391  
; Sequenced  
; Patent  
; GENERAL  
; APP  
; TIT  
; TIT  
; TIT  
; NUM